Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
Condition(s) studied
Investigational drug(s) / intervention(s)
Lithium: The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
Cariprazine: The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
Study summary
The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease.
The main question it aims to answer is:
Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6)
Participants will be randomized to treatment with either lithium or cariprazin.
* Will meet for interview and ratings 4 times during study period.
* In two meetings, there will be made blood samples and ECG. At one meeting also a Urine sample.
* Will be contacted for telephone interviews at 6 occasions.
Eligibility
Primary outcome measure(s)
- Change in Hamilton Depressions scale, version 6 (HDS-6) — 8 weeks
The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Aalborg University Hospital | Aalborg | Denmark | Recruiting |
More Aalborg University Hospital trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05913947 on ClinicalTrials.gov ↗ ← All trials in Denmark